TVTX - Ligand Pharmaceuticals: Expanding Royalty Portfolio And Strong Drug Pipeline
2023-03-25 10:30:03 ET
Summary
- Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline.
- Ligand Pharmaceuticals has recently announced several positive developments, including the submission of an NDA by its partner Novan for the treatment of molluscum contagiosum and the accelerated approval of Filspari.
- Ligand is entitled to receive net milestone payments and royalties on future global net product sales of sparsentan, which is the first and only non-immunosuppressive therapy approved for the treatment.
For further details see:
Ligand Pharmaceuticals: Expanding Royalty Portfolio And Strong Drug Pipeline